ARCA Biopharma, Inc.
12
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
16.7%
2 terminated/withdrawn out of 12 trials
80.0%
-6.5% vs industry average
33%
4 trials in Phase 3/4
25%
2 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19
Role: lead
Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
Role: lead
Study of NU172 as Anticoagulation in Patients Undergoing Off-pump CABG Surgery
Role: lead
Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices
Role: lead
Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion
Role: lead
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters
Role: lead
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters
Role: lead
Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer
Role: lead
Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke
Role: lead
Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery
Role: lead
Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
Role: lead
Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32
Role: lead
All 12 trials loaded